MD, Cornell University Medical College
Residency, Internal Medicine
New York Hospital
Fellowship, Digestive Disease
Yale University School of Medicine
Dr. Ullman's major research focus is cancer in inflammatory bowel disease. His work includes identification of the clinical risk factors for colon cancer in IBD. He has conducted studies detailing the natural history of dysplasia in ulcerative colitis, the influence of inflammation on carcinogenesis in IBD, and the relative chemopreventive effects of a number of therapies used in UC. Additionally, Dr. Ullman is pursuing research into biomarkers of disease diagnosis and activity in IBD, and the outcomes of patients with Crohn's disease and ulcerative colitis treated with cyclosporine A.
Ullman T, Odze R, Farraye FA. Diagnosis and Management of Dysplasia in Patients with Ulcerative Colitis and Crohn's Disease of the Colon [Epub ahead of print]. Inflamm Bowel Dis;.
Ullman T, Croog V, Harpaz N, Hossain S, Kornbluth A, Bodian C, Itzkowitz S. Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of 5-Aminosalicylic Acid. Clin Gastro and Hepatol 2008; 6: 1225-1230.
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105.
Ullman TA, Palmon R. The Certain Uncertainty of Measuring Disease Activity in IBD. J Clin Gastroenterol 2007; 41: 123-125.
Matula S, Croog V, Itzkowitz S, Harpaz N, Bodian C, Hossain S, Ullman T. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005 October; 3(10): 1015-1021.
Ullman T, Croog V, Harpaz N, Sachar D, Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125(5): 1311-1319.
Ullman TA. Patients with LGD Should Be Advised to Undergo Surgery. Inflamm Bowel Dis 2003; 9: 267-269.
Ullman TA, Loftus EV, Kakar S, Burgart LJ, Sandborn WJ, Tremaine WJ. The Fate of Low Grade Dysplasia in Ulcerative Colitis. The American Journal of Gastroenterology 2002; 97: 922-927.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Ullman during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.